Arkolith/Insider Trading/EVLO/Form 4

Gill Simba

President & CEO, DirectorEvelo Biosciences, Inc. (EVLO) · full profile →Form 4 · filed Aug 9, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3K
Net Open-Market Flow
-$3K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 8, 2023Sell(S)342$9.51$3K4K
Aug 7, 2023Option exercise(M)1K——4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 7, 2023Option exercise(M)1K—$016K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001694665-23-000135) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML